Revolution Medicines, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 8.46M | $823.15M | 0.04% | Trimmed-1.4% | 2026-03-31 |
| Wellington | fundamental | 6.03M | $586.21M | 0.11% | Trimmed-13.7% | 2026-03-31 |
| StateStreet | passive | 4.40M | $428.16M | 0.01% | Added+7.1% | 2026-03-31 |
| TwoSigma | quant | 1.56M | $151.59M | 0.12% | Added+269.6% | 2026-03-31 |
| DEShaw | quant | 1.02M | $99.42M | 0.06% | Trimmed-36.6% | 2026-03-31 |
| RenTech | quant | 6.2K | $602.95K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 3.23M | $314.33K | 0.04% | Trimmed-5.1% | 2026-03-31 |